Will that Be One Dose or Two? U.S. Buying 100 Million More Doses of Johnson & Johnson’s One-Shot Vaccine

Sure, it has slightly lower efficacy than the Pfizer (PFE) and Moderna (MRNA) vaccines, but the Johnson & Johnson (JNJ) shot has the incredible advantage of not requiring a second shot. With America so torn on the merits and health risks of the two-shot vaccine, there are lots of people who would like the single-shot solution.

Read More ›

AstraZeneca Flips Moderna Profits to Expand into Line of Rare-Disease Drugs

While AstraZeneca’s (AZN) COVID-19 vaccine still awaits approval for use in the U.S., the drugmaker is still cashing in on the progress of vaccines here in the states. Nicknamed the Oxford-vaccine, AstraZeneca’s vaccine, which has only gained approval in Europe, trails drugmakers Pfizer (PFE), BioNTech (BNTX) and Moderna (MRNA) in the U.S., yet still managed

Read More ›

While the Public is Still on the Fence, it Looks Like Washginton is Sold on the Pfizer Vaccine

With countless polls across the country from a variety of sources, including this one from the Associated Press, reporting that roughly half of all Americans are still very much on the fence about getting the COVID-19 vaccine, the U.S. Government continues to march forward. Today, it was announced that Pfizer (PFE) and its drugmaking partner BioNTech

Read More ›

Market Overview